LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
LENZ Therapeutics, Inc. reported fourth quarter and full year 2025 financial results and recent corporate highlights on March 24, 2026. The company had previously announced on January 7, 2026 that it expected fourth quarter 2025 preliminary unaudited financial results. Additional corporate updates include a Marketing Authorization Application submission to the European Medicines Agency for VIZZ, a commercialization partnership with Lunatus for the Middle East, and an NDA submission to MFDS in South Korea for pre...
Key takeaways
LENZ Therapeutics reported Q4 and full year 2025 financial results on March 24, 2026
Preliminary Q4 2025 unaudited results were announced on January 7, 2026
Company submitted Marketing Authorization Application to European Medicines Agency for VIZZ in March 2026
Exclusive commercialization partnership announced with Lunatus for VIZZ in the Middle East
NDA submitted to MFDS in South Korea for LNZ100 (VIZZ) for presbyopia treatment
Consumer campaign 'Make it VIZZable' launched with Sarah Jessica Parker in January 2026
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open Investor relationsFollow LENZ in real time
Get material earnings, filing, IR, and earnings-call alerts by email.